Is HDL a prognostic biomarker for coronary atherosclerosis?

International Journal of Cardiology

Volumn 174, Issue 3, 2014, Pages 465-467

  Papageorgiou, Nikolaos ^a   Tousoulis, Dimitris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; CVD; HDL; Prognosis

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EDITORIAL; EVIDENCE BASED MEDICINE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; BLOOD;

BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; HUMANS; PROGNOSIS;

EID: 84903270290     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.04.227     Document Type: Editorial

References (19)

1. A. Milwidsky, S. Kivity, and E. Kopel et al. Time dependent changes in high density lipoprotein cholesterol and cardiovascular risk Int J Cardiol 173 2 2014 295 299
2. M. Marcil, R. Bissonnette, J. Vincent, L. Krimbou, and J. Genest Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiency Circulation 107 2003 1366 1371
3. B.F. Asztalos, P.S. Roheim, and R.L. Milani et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease Arterioscler Thromb Vasc Biol 20 2000 2670 2676
4. B.F. Asztalos, L.A. Cupples, and S. Demissie et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study Arterioscler Thromb Vasc Biol 24 2004 2181 2187
5. S. Acharjee, W.E. Boden, and P.M. Hartigan et al. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) J Am Coll Cardiol 62 2013 1826 1833
6. S. Acharjee, M.T. Roe, E.A. Amsterdam, D.N. Holmes, and W.E. Boden Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry) Am J Cardiol 112 2013 1057 1062
7. A.P. van de Woestijne, Y. van der Graaf, and A.H. Liem et al. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication J Am Coll Cardiol 62 2013 1834 1841
8. S. Zewinger, T. Speer, and M.E. Kleber et al. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction J Am Soc Nephrol 25 2014 1073 1082
9. E. Angeloni, F. Paneni, and U. Landmesser et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting Eur Heart J 34 2013 3557 3562
10. G.G. Schwartz, A.G. Olsson, and M. Abt et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
11. J.C. Tardif, J. Grégoire, and P.L. L'Allier et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
12. M.H. Frick, M. Syvänne, and M.S. Nieminen et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group Circulation 96 1997 2137 2143
13. C.G. Ericsson, A. Hamsten, J. Nilsson, L. Grip, B. Svane, and U. de Faire Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients Lancet 347 1996 849 853
14. H.B. Rubins, S.J. Robins, and D. Collins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
15. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
16. J.P. Kane, M.J. Malloy, T.A. Ports, N.R. Phillips, J.C. Diehl, and R.J. Havel Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 264 1990 3007 3012
17. G. Brown, J.J. Albers, and L.D. Fisher et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
18. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
19. R. Haynes, L. Jiang, and J.C. Hopewell et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291